Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High dose rate brachytherapy of localized prostate cancer.
Deger S, Boehmer D, Türk I, Roigas J, Wernecke KD, Wiegel T, Hinkelbein W, Dinges S, Budach V, Loening SA. Deger S, et al. Among authors: wernecke kd. Eur Urol. 2002 Apr;41(4):420-6. doi: 10.1016/s0302-2838(02)00016-7. Eur Urol. 2002. PMID: 12074814
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Budach V, et al. Among authors: wernecke kd. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24. doi: 10.1016/j.ijrobp.2014.12.034. Epub 2015 Feb 7. Int J Radiat Oncol Biol Phys. 2015. PMID: 25670541 Clinical Trial.
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Budach V, et al. Among authors: wernecke kd. J Clin Oncol. 2005 Feb 20;23(6):1125-35. doi: 10.1200/JCO.2005.07.010. J Clin Oncol. 2005. PMID: 15718308 Clinical Trial.
Validity and reliability of the DDS for severity of delirium in the ICU.
Otter H, Martin J, Bäsell K, von Heymann C, Hein OV, Böllert P, Jänsch P, Behnisch I, Wernecke KD, Konertz W, Loening S, Blohmer JU, Spies C. Otter H, et al. Among authors: wernecke kd. Neurocrit Care. 2005;2(2):150-8. doi: 10.1385/NCC:2:2:150. Neurocrit Care. 2005. PMID: 16159057
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.
Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K; Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group. Lüftner D, et al. Among authors: wernecke kd. Breast Cancer Res Treat. 2003 Aug;80(3):245-55. doi: 10.1023/a:1024911625339. Breast Cancer Res Treat. 2003. PMID: 14503797 Clinical Trial.
Noninvasive monitoring of myocardial function after surgical and cytostatic therapy in a peritoneal metastasis rat model: assessment with tissue Doppler and non-Doppler 2D strain echocardiography.
Hartmann J, Knebel F, Eddicks S, Beling M, Grohmann A, Panda A, Jacobi CA, Müller JM, Wernecke KD, Baumann G, Borges AC. Hartmann J, et al. Among authors: wernecke kd. Cardiovasc Ultrasound. 2007 Jul 12;5:23. doi: 10.1186/1476-7120-5-23. Cardiovasc Ultrasound. 2007. PMID: 17626632 Free PMC article.
322 results